A study of a cohort of 19,337 incident insulin users from the Netherlands found a decreased risk for overall and colon cancer but no difference in risk for bladder, respiratory tract and prostate cancer, when comparing time-dependently defined cumulative time using insulin glargine to that using human insulin, though without further distinction between different treatment durations [39]. This evidence concerns the gene INS and prostate carcinoma.